NEW YORK (GenomeWeb) — Sophia Genetics and ArcherDx today announced that they have formed a partnership to combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.
Under the terms of the deal, Sophia will incorporate ArcherDx's FusionPlex, VariantPlex, and Reveal ctDNA kits into its Data-Driven Medicine analytical platform, and offer the combined solutions to its network of more than 215 hospital and laboratory customers globally.
"By joining forces, ArcherDX and Sophia Genetics are enabling international laboratories of all sizes using [Sophia's artificial intelligence technology] to access and report on cutting-edge applications that ArcherDX has developed, including gene fusions, liquid biopsies, and immune repertoire profiling," ArcherDx CEO Jason Myers said in a statement.
The companies said their partnership launches immediately. Additional terms of the arrangement were not disclosed.